anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Array analysis has become a standard technique for molecular biologists who wish to monitor gene expression. DNA ink-jet printer technology has had a significant impact on genomics, biology, and medicine.
Anti-fouling coatings. Anti-microbial coatings. Anti-reflective coatings for example on spectacles. Coatings that alter or have magnetic, electrical or electronic properties. Flame retardant coatings. Flame-retardant materials and coatings are being developed that are phosphorus and bio-based. These include coatings with intumescent functionality. Non-stick PTFE coated cooking pots/pans. Optical coatings are available that alter optical properties of a material or object. UV coatings
In Greek legend there was a fighter named Antaeus who drew strength from the earth even when he was flung down. It took Hercules to work out his vulnerability as a wrestler. Hezbollah loves death, thrives on defeat and disaster, and is rapidly moving from being a state within a state to becoming the master of what was once the most cosmopolitan and democratic country in the Middle East. Meanwhile, a former superpower – no Hercules – is permitting itself to be made a hostage and laughing-stock by a squalid factional fight within the Israeli right wing involving the time and scale of petty land theft by zealots and fanatics. Only a few years from now, this, too, will seem hard to believe, as well as shameful and unpardonable.
AABB publishes a variety of other materials for the blood and biotherapies field, including the standards by which it accredits institutions. Since 1953, the organization has also operated a National Blood Exchange to facilitate transfers of blood products during shortages or when rare blood types are required. On June 1, 2018, Debra BenAvram, FASAE, CAE, became the association's chief executive officer (CEO).
or 140 different polypeptides in the library. This peptide library would be useful for analyzing the effect of the post-translational modification acetylation on lysine which neutralizes the positive charge. Having the library of different peptides at residue 2 and 3 would let the investigator see if some change in chemical properties in the N-terminal tail of the ligated protein makes the protein more useful or useful in a different way.
Sources: en.wikipedia.org
Some women with ptosis choose to undergo plastic surgery to make their breasts less ptotic. Plastic surgeons offer several procedures for lifting sagging breasts. Surgery to correct the size, contour, and elevation of sagging breasts is called mastopexy. Women can also choose breast implants, or may undergo both procedures. The breast-lift procedure surgically elevates the parenchymal tissue (breast mass), cuts and re-sizes the skin envelope, and transposes the nipple-areola complex higher upon the breast hemisphere. If sagging is present and the woman opts not to undergo mastopexy, implants are typically placed above the muscle, to fill out the breast skin and tissue. Submuscular placement can result in deformity. In these cases, the implant appears to be high on the chest, while the natural breast tissue hangs down over the implant.
Compared to the United Monarchy, the historicity of the Kingdom of Israel and Judah is widely accepted by historians and archaeologists. Their destruction by the Assyrians and Babylonians respectively is also confirmed by archaeological evidence and extrabiblical sources. Christian Frevel argues that Yahwism was rooted in the culture of the Kingdom of Israel, who introduced it to the Kingdom of Judah via Ahab's expansions and sociopolitical cooperation, which was prompted by Hazael's conquests. Frevel has also argued that Judah was a 'vassal-like' state to Israel, under the Omrides. This theory has been rejected by other scholars, who argue that the archaeological evidence seems to indicate that Judah was an independent socio-political entity for most of the 9th century BCE. Avraham Faust argues that there was continued adherence to the 'ethos of egalitarianism and simplicity' in the Iron Age II (10th-6th century BCE). For example, there is minimal evidence of temples and complex tomb burials, despite Israel and Judah being more densely populated than the Late Bronze Age. Four-room houses remained the norm. In addition, royal inscriptions were scarce, along with imported and decorated pottery. According to William G. Dever, Israelite identity in the 9th-8th centuries BCE can be identified through a combination of archaeological and cultural traits that distinguish them from their neighbours.
=== Psoriatic arthritis === In psoriatic arthritis (PsA), inhibitors of TNF, such as infliximab, improve the signs and symptoms. Several therapies with modest efficacy have been studied in nail psoriasis. Among available agents, higher quality data are available to support the efficacy of cyclosporine and infliximab. Based on studies in AS, the results suggest infliximab, etanercept, and adalimumab have the potential to reduce the signs and symptoms of moderate to severely active axial involvement in PsA in patients who have had an inadequate response to NSAID (level 1a, grade A). The anti-TNF agents (infliximab and etanercept; level 1b, grade A) are more effective for the treatment of enthesitis than traditional agents. Results suggest infliximab is effective for the treatment of dactylitis in PsA.
Morphine, or any salt of morphine, ester of morphine or salt of ester of morphine (§6, (2)); Diamorphine (heroin) or any salt of diamorphine (§6, (3)); Cocaine or any salt of cocaine (§6, (4)); Methamphetamine (§6, (5)). Under the Act:
=== Conflict wounds === In 2018, the Scar Free Foundation Centre for Conflict Wound Research was established at the Royal Centre for Defence Medicine in Queen Elizabeth Hospital, Birmingham. The centre's studies aim to mitigate the physical and psychological impacts of scarring among servicemen, women, and individuals injured in terrorist attacks. It was established in partnership with the CASEVAC Club, a members organisation similar to the Guinea Pig Club.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.